Oramed Pharmaceuticals (ORMP) Return on Capital Employed (2011 - 2026)

Oramed Pharmaceuticals has reported Return on Capital Employed for 15 years, with the latest figure at 6.96% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 1031.0% year-over-year to 6.96%; the trailing twelve-month figure through Mar 2026 stood at 6.96% (up 1031.0% YoY), and the FY2025 full-year result was 9.09%, up 1093.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 6.96%, down from 7.66% in the prior quarter.
• The five-year high for Return on Capital Employed was 7.66% in Q4 2025, with the low at 35.12% in Q3 2022.
• Historically, Return on Capital Employed has averaged 9.55% across 5 years, with a median of 2.81% in 2025.
• The largest YoY upside for Return on Capital Employed was 2807 bps in 2023 against a maximum downside of 714 bps in 2023.
• Oramed Pharmaceuticals' Return on Capital Employed stood at 27.45% in 2022, then surged by 102 bps to 0.62% in 2023, then tumbled by 450 bps to 2.16% in 2024, then jumped by 454 bps to 7.66% in 2025, then fell by 9 bps to 6.96% in 2026.
• The last three Return on Capital Employed figures came in at 6.96% (Q1 2026), 7.66% (Q4 2025), and 1.93% (Q3 2025), per Business Quant data.